Fosrenol Post-marketing Surveillance in Japan

Status Completed

Clinical Trial Summary

This study is a regulatory post-marketing surveillance in Japan and it is a local prospective and observational study of patients who have received Fosrenol.

The objective of this research is to collect information on the safety of Fosrenol after its launching, which means collecting information on adverse events, especially adverse events in the digestive system including constipation and serious adverse events, and adverse drug reactions when the drug is administered to the below-mentioned target patients for six months.

The secondary objective is to collect information on the safety of the drug when administered for more than six months, which means collecting information on the safety of the drug when administered for up to 12 months to the target patients who have already been treated with the drug for six months. And also if at the time of 12 months after administration of Lanthanum carbonate the dialysis is not conducted, extending its' administration will be continued until conduction of dialysis, or until Sept. 30, 2015. The efficacy of fosrenol is evaluated by observing the serum P(phosphorus) level and serum PTH (parathyroid hormone) level change.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01955876
Study type	Observational
Source	Bayer
Contact
Status	Completed
Phase	N/A
Start date	October 10, 2013
Completion date	August 5, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02369354` - Transplant Social Worker Support for Live Kidney Donation in African Americans	N/A
Not yet recruiting	`NCT02225782` - Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function	Phase 4
Completed	`NCT00499187` - Fanconi Syndrome Due to ARVs in HIV-Infected Persons	Phase 4
Completed	`NCT00379899` - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis	Phase 4
Withdrawn	`NCT00585429` - Evaluation of Kidney Disease in Liver Transplant Recipients	N/A
Completed	`NCT00183248` - Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients	Phase 1/Phase 2
Completed	`NCT00001835` - Oxaliplatin in Cancer Patients With Impaired Kidney Function	Phase 1
Completed	`NCT01331941` - A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function	Phase 1
Terminated	`NCT00436748` - Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease	Phase 3
Completed	`NCT01467466` - Prevention of Serious Adverse Events Following Angiography	Phase 3
Completed	`NCT01235936` - Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia	Phase 2
Completed	`NCT01974999` - A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study
Completed	`NCT01947829` - Interdialytic Kt/V Variability Measurement With Adimea (IVP STUDY)	N/A
Recruiting	`NCT01240564` - The Nephrotic Syndrome Study Network (NEPTUNE)	N/A
Active, not recruiting	`NCT01228903` - Uric Acid and the Endothelium is CKD	N/A
Completed	`NCT00734357` - Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients	N/A
Completed	`NCT00781417` - Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease	N/A
Completed	`NCT00094484` - Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis	Phase 3
Completed	`NCT00185159` - Olmesartan Medoxomil in Diabetes Mellitus	Phase 3
Completed	`NCT00096915` - Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis	Phase 3